Subcutaneous recombinant gamma interfero
โ
John A. Thompson; W. Welby Cox; Catherine G. Lindgren; Carolyn Collins; Kathryn
๐
Article
๐
1987
๐
Springer-Verlag
๐
English
โ 750 KB
Recombinant gamma interferon (ry-IFN) was administered s. c. daily to 26 patients with advanced cancer. Patients were assigned to one of six doses: 0.5, 1, 2, 4, 6, or 8 million units (MU)/m 2 per d. The major toxicities were an influenza-like syndrome and fever, seen in all patients. Dose limiting